Question · asked by 1 review
Pilocarpine lozenge (3 mg or 5 mg) vs placebo control: Salivary flow rate
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Pilocarpine lozenge (3 mg or 5 mg) vs Placebo lozenge Salivary flow (saliva production) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's… · Single dose (up to 3 hours) Interventions for the management of dry mouth: topical therapies (2011) · Cochrane All outcomes | Statistically significant increase in saliva production vs placebo (P <= 0.05); maximum salivary output 60 to 90 minutes post-lozenge; no data presented. | 1 study · 33 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for the management of dry mouth: topical therapies 2011 · Cochrane All outcomes | 2011-10 | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.